Aug. 28 (UPI) --When treating blocked arteries, a removable balloon is just as effective as a permanent stent, according to a study. The BASKET-SMALL 2 trial, the largest randomized study, compared ...
The US Food and Drug Administration (FDA) has approved Boston Scientific's Agent Drug-Coated Balloon (DCB), the first coronary DCB for the treatment of coronary in-stent restenosis in patients with ...
In the treatment of larger narrowed blood vessels, drug-coated balloon catheters have been shown to deliver lasting and effective outcomes. Their minimally invasive nature makes them a viable ...
A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...
A paclitaxel-coated balloon is superior to an uncoated balloon for the composite end point of target lesion failure among patients undergoing coronary angioplasty for in-stent restenosis, according to ...
Please provide your email address to receive an email when new articles are posted on . A sirolimus-eluting balloon was noninferior to drug-eluting stents in treating de novo coronary lesions. The ...
In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results